肺癌靶向药物治疗研究进展  

Research Progress in Medicine Targeted Therapy for Lung Cancer

作　　者：杨瑜[1] Yang Yu(Department of Pharmacy,Zhongnan Hospital of Wuhan University,Wuhan 430071,China)

机构地区：[1]武汉大学中南医院药剂科,武汉430071

出　　处：《中国药师》2019年第1期140-143,共4页China Pharmacist

摘　　要：肺癌是目前最常见的恶性肿瘤之一,其存在被认为源于致癌启动基因的突变。因此,在肺癌患者中,急需针对基因突变的治疗手段。靶向药物治疗是针对肿瘤细胞及其生长微环境,使用相应的阻滞药物抑制肿瘤的生长与增殖,其治疗针对性更强,对正常细胞不良反应更低。近年来,新的靶点和新的靶向药物不断出现,本文回顾及展望肺癌靶向药物治疗的研究进展。Lung cancer is a most common malignancy in the world,which is thought to result from mutations in the major carcinogenic genes.Therefore,treatment for mutation is urgently needed by lung cancer patients.Targeted medicine therapy is directly against tumor cells and their growth microenvironment by using corresponding blockers to inhibit tumor growth and proliferation.Targeted medicine therapy aims better and lowers side effects on normal cells.In recent years,new targets and new targeting drugs have been emerging.The paper summarized the recent researches on medicine targeted therapy for lung cancer.

关 键 词：肺癌 基因突变 靶向药物 研究进展 

分 类 号：R979.1[医药卫生—药品]